Cholesterol
CV medications underused by Hispanic/Latino patients with PAD
Hispanic and Latino patients with peripheral artery disease underuse guideline-recommended CV medications such as antiplatelet and lipid-lowering therapies, researchers found.
Machine learning algorithm identifies FH in health care system
A machine learning algorithm to identify patients with familial hypercholesterolemia was successfully implemented in a large health care system, according to a presentation.
ODYSSEY HoFH
LDL reduction with alirocumab (Praluent, Sanofi/Regeneron) every 2 weeks vs. placebo in patients with homozygous familial hypercholesterolemia.
Endocrine-disrupting chemical exposure during pregnancy influences obesity across two generations
Exposure to a class of endocrine-disrupting chemicals known as perfluoroalkyl and polyfluoroalkyl substances, or PFAS, during pregnancy can influence obesity in granddaughters two generations later, according to findings accepted for presentation at the Endocrine Society Annual Meeting.
Alirocumab, evinacumab confer LDL benefit in homozygous familial hypercholesterolemia
Two studies presented at the virtual American College of Cardiology Scientific Session highlight new options for LDL cholesterol reduction in patients with homozygous familial hypercholesterolemia.
Gestational diabetes exposure tied to higher cholesterol, BP in children
Exposure to gestational diabetes in utero is associated with worse cardiovascular health in offspring from childhood through adolescence, according to an analysis of health plan data published in Pediatric Obesity.
Top primary care stories in 2019: Rethinking red meat, flu shot timing and more
Non-HDL may be linked to ASCVD risk
Non-HDL was strongly linked to long-term risk for atherosclerotic CVD, as shown by a tool for long-term risk assessment, according to a study published in The Lancet.
Highlights from FH Global Summit: Cholesterol medication underuse, screening and more
Healio and Cardiology Today present meeting highlights from the FH Foundation’s FH Global Summit on familial hypercholesterolemia, featuring the latest news in the use of cholesterol medication, patient screening, artificial intelligence and more.